<p>Elyxium Wealth LLC 在最近向证券交易委员会（SEC）披露的文件中表示，在第四季度购买了 IDEXX Laboratories, Inc.（NASDAQ:IDXX - 免费报告）的新股份。该公司购买了 5,419,507 股，价值约为 36.66 亿美元。IDEXX Laboratories 占 Elyxium Wealth LLC 投资组合的约 54.3%，成为其最大持股。Elyxium Wealth LLC 在最近一个季度末持有 IDEXX Laboratories 的 6.79%。</p>
<p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
<ul>
<li>看涨还是看跌？评估动物医疗保健股票</li>
</ul>
<p>其他一些对冲基金最近也调整了对 IDXX 的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 IDEXX Laboratories 的持股增加了 0.9%。先锋集团目前拥有 9,962,025 股该公司的股票，价值 63.65 亿美元，在上个季度又购买了 86,040 股。纽约梅隆银行（Bank of New York Mellon Corp）在第三季度将其在 IDEXX Laboratories 的持股增加了 41.7%。纽约梅隆银行目前拥有 2,056,680 股该公司的股票，价值 13.14 亿美元，在上个季度又购买了 605,290 股。西北互助财富管理公司（Northwestern Mutual Wealth Management Co.）在第四季度将其在 IDEXX Laboratories 的持股增加了 63,503.9%。西北互助财富管理公司目前拥有 1,444,445 股该公司的股票，价值 9.77 亿美元，在上个季度又购买了 1,442,174 股。英维斯科（Invesco Ltd.）在第三季度将其在 IDEXX Laboratories 的持股增加了 14.0%。英维斯科目前拥有 1,320,263 股该公司的股票，价值 8.44 亿美元，在上个季度又购买了 161,782 股。最后，首席金融集团（Principal Financial Group Inc.）在第三季度将其在 IDEXX Laboratories 的持股增加了 16.7%。首席金融集团目前拥有 1,315,722 股该公司的股票，价值 8.41 亿美元，在上个季度又购买了 187,967 股。机构投资者和对冲基金目前持有该公司 87.84% 的股票。</p>
<h2>IDEXX Laboratories 股票表现</h2>
<p>NASDAQ IDXX 的股票周一开盘价为 528.79 美元。该公司的流动比率为 1.12，速动比率为 0.82，债务与股本比率为 0.19。IDEXX Laboratories, Inc. 的 12 个月低点为 496.61 美元，12 个月高点为 769.98 美元。该股票的 50 日移动平均线为 572.08 美元，200 日移动平均线为 645.55 美元。该公司的市值为 417.1 亿美元，市盈率为 38.94，市盈增长比率为 3.07，贝塔系数为 1.58。</p>
<p>IDEXX Laboratories（NASDAQ:IDXX - 获取免费报告）最近于 5 月 5 日发布了季度财报。该公司报告每股收益为 3.47 美元，超出市场共识预期的 3.41 美元，超出幅度为 0.06 美元。该季度的营业收入为 11.4 亿美元，而分析师预期为 11.2 亿美元。IDEXX Laboratories 的股本回报率为 70.87%，净利润率为 24.63%。该公司的季度收入同比增长 14.3%。去年同期，该公司每股收益为 2.91 美元。IDEXX Laboratories 将其 2026 财年的每股收益指引设定在 14.450-14.900 美元。整体来看，股票研究分析师预测 IDEXX Laboratories, Inc. 今年将发布 14.68 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在相关消息中，执行副总裁 Nimrata Hunt 于 2 月 26 日星期四出售了 2,693 股该公司的股票。股票以平均价格 661.54 美元出售，总交易额为 1,781,527.22 美元。出售完成后，该执行副总裁直接持有 19,899 股公司股票，价值 13,163,984.46 美元。这代表其持股减少了 11.92%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，执行副总裁 Michael G. Erickson 于 2 月 17 日星期二出售了 5,371 股该公司的股票。股票以平均价格 627.38 美元出售，总价值为 3,369,657.98 美元。出售后，该执行副总裁持有 12,693 股该公司的股票，价值约为 7,963,334.34 美元。这代表其持股减少了 29.73%。该交易的 SEC 备案提供了更多信息。过去 90 天内，内部人士共出售了 34,612 股公司股票，价值 22,525,070 美元。当前 0.79% 的股票由内部人士持有。</p>
<h2>分析师设定新目标价</h2>
<p>IDXX 最近成为多份研究报告的主题。花旗集团（Citigroup）在 4 月 15 日星期三发布的报告中对 IDEXX Laboratories 开始覆盖。他们为该公司设定了 “中性” 评级和 650.00 美元的目标价。BTIG Research 在 2 月 3 日星期二的报告中将 IDEXX Laboratories 的目标价从 830.00 美元下调至 800.00 美元，并为该公司设定了 “买入” 评级。Stifel Nicolaus 在 3 月 31 日星期二的研究报告中将 IDEXX Laboratories 的目标价从 775.00 美元下调至 675.00 美元，并为该公司设定了 “买入” 评级。巴克莱（Barclays）在 2 月 5 日星期四的研究报告中将 IDEXX Laboratories 的目标价从 850.00 美元下调至 800.00 美元，并为该公司设定了 “增持” 评级。最后，瑞银集团（UBS Group）在 4 月 28 日星期二的研究报告中将 IDEXX Laboratories 的目标价从 730.00 美元下调至 640.00 美元，并为该公司设定了 “中性” 评级。七位分析师对该股票给予了 “买入” 评级，四位分析师给予了 “持有” 评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价为 751.00 美元。</p>
<p><strong>获取我们关于 IDXX 的最新研究报告</strong></p>
<h2>关于 IDEXX Laboratories</h2>
<p>（免费报告）</p>
<p>IDEXX Laboratories, Inc NASDAQ: IDXX 是一家全球开发、制造和提供诊断产品及服务的公司，主要面向动物健康、水质检测和食品安全市场。公司总部位于缅因州的韦斯特布鲁克，提供临床诊断仪器、耗材、参考实验室检测和实践管理工具，支持全球的兽医、畜牧和乳制品生产者，以及公用事业和食品生产者。</p>
<p>IDEXX 的产品组合包括用于兽医诊所快速诊断的即时检测和免疫测定、临床化学和血液学分析仪、自动化尿液分析系统以及数字诊断解决方案。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 IDEXX Laboratories 更好的股票</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>随着博通市值突破 2 万亿美元，私人信贷巨头想要入场</li>
<li>通过这些 ETF 关注火热的分拆和合并领域</li>
<li>随着 AI 内存需求激增，三星加入 1 万亿美元俱乐部</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
<p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 IDEXX Laboratories 并不在名单上。</p>
<p>虽然 IDEXX Laboratories 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IDEXX实验室

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

<p>Elyxium Wealth LLC 已投资 36.7 亿美元于 IDEXX Laboratories，收购了 5,419,507 股，现占其投资组合的 54.3%。其他机构投资者也增加了对 IDEXX 的持股。该公司的股票开盘价为 528.79 美元，市值为 417.1 亿美元，市盈率为 38.94。IDEXX 报告的季度每股收益为 3.47 美元，超出预期，并已将 2026 财年的指导目标设定为 14.450-14.900 每股收益</p>

<p>Elyxium Wealth LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,419,507 shares of the company's stock, valued at approximately $3,666,459,000. IDEXX Laboratories accounts for about 54.3% of Elyxium Wealth LLC's investment portfolio, making the stock its biggest holding. Elyxium Wealth LLC owned 6.79% of IDEXX Laboratories at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Elyxium Wealth LLC 在最近向证券交易委员会（SEC）披露的文件中表示，在第四季度购买了 IDEXX Laboratories, Inc.（NASDAQ:IDXX - 免费报告）的新股份。该公司购买了 5,419,507 股，价值约为 36.66 亿美元。IDEXX Laboratories 占 Elyxium Wealth LLC 投资组合的约 54.3%，成为其最大持股。Elyxium Wealth LLC 在最近一个季度末持有 IDEXX Laboratories 的 6.79%。</p>
</div><p>Get <strong>IDEXX Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物医疗保健股票</li>
</ul>
</div><p>A number of other hedge funds also recently modified their holdings of IDXX. Vanguard Group Inc. grew its holdings in shares of IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company's stock worth $6,364,638,000 after buying an additional 86,040 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of IDEXX Laboratories by 41.7% during the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company's stock worth $1,313,992,000 after buying an additional 605,290 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company's stock worth $977,210,000 after buying an additional 1,442,174 shares in the last quarter. Invesco Ltd. grew its holdings in shares of IDEXX Laboratories by 14.0% during the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company's stock worth $843,503,000 after buying an additional 161,782 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company's stock worth $840,638,000 after buying an additional 187,967 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也调整了对 IDXX 的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 IDEXX Laboratories 的持股增加了 0.9%。先锋集团目前拥有 9,962,025 股该公司的股票，价值 63.65 亿美元，在上个季度又购买了 86,040 股。纽约梅隆银行（Bank of New York Mellon Corp）在第三季度将其在 IDEXX Laboratories 的持股增加了 41.7%。纽约梅隆银行目前拥有 2,056,680 股该公司的股票，价值 13.14 亿美元，在上个季度又购买了 605,290 股。西北互助财富管理公司（Northwestern Mutual Wealth Management Co.）在第四季度将其在 IDEXX Laboratories 的持股增加了 63,503.9%。西北互助财富管理公司目前拥有 1,444,445 股该公司的股票，价值 9.77 亿美元，在上个季度又购买了 1,442,174 股。英维斯科（Invesco Ltd.）在第三季度将其在 IDEXX Laboratories 的持股增加了 14.0%。英维斯科目前拥有 1,320,263 股该公司的股票，价值 8.44 亿美元，在上个季度又购买了 161,782 股。最后，首席金融集团（Principal Financial Group Inc.）在第三季度将其在 IDEXX Laboratories 的持股增加了 16.7%。首席金融集团目前拥有 1,315,722 股该公司的股票，价值 8.41 亿美元，在上个季度又购买了 187,967 股。机构投资者和对冲基金目前持有该公司 87.84% 的股票。</p>
</div><h2>IDEXX Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 股票表现</h2>
</div><p>Shares of NASDAQ IDXX opened at $528.79 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $496.61 and a 12 month high of $769.98. The stock has a 50 day moving average of $572.08 and a 200-day moving average of $645.55. The company has a market capitalization of $41.71 billion, a P/E ratio of 38.94, a P/E/G ratio of 3.07 and a beta of 1.58.</p>
<div class="lb-trans"><p>NASDAQ IDXX 的股票周一开盘价为 528.79 美元。该公司的流动比率为 1.12，速动比率为 0.82，债务与股本比率为 0.19。IDEXX Laboratories, Inc. 的 12 个月低点为 496.61 美元，12 个月高点为 769.98 美元。该股票的 50 日移动平均线为 572.08 美元，200 日移动平均线为 645.55 美元。该公司的市值为 417.1 亿美元，市盈率为 38.94，市盈增长比率为 3.07，贝塔系数为 1.58。</p>
</div><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts' expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.</p>
<div class="lb-trans"><p>IDEXX Laboratories（NASDAQ:IDXX - 获取免费报告）最近于 5 月 5 日发布了季度财报。该公司报告每股收益为 3.47 美元，超出市场共识预期的 3.41 美元，超出幅度为 0.06 美元。该季度的营业收入为 11.4 亿美元，而分析师预期为 11.2 亿美元。IDEXX Laboratories 的股本回报率为 70.87%，净利润率为 24.63%。该公司的季度收入同比增长 14.3%。去年同期，该公司每股收益为 2.91 美元。IDEXX Laboratories 将其 2026 财年的每股收益指引设定在 14.450-14.900 美元。整体来看，股票研究分析师预测 IDEXX Laboratories, Inc. 今年将发布 14.68 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, EVP Nimrata Hunt sold 2,693 shares of the company's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the sale, the executive vice president directly owned 19,899 shares in the company, valued at $13,163,984.46. This represents a 11.92% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Michael G. Erickson sold 5,371 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares of the company's stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 34,612 shares of company stock valued at $22,525,070 over the last 90 days. 0.79% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Nimrata Hunt 于 2 月 26 日星期四出售了 2,693 股该公司的股票。股票以平均价格 661.54 美元出售，总交易额为 1,781,527.22 美元。出售完成后，该执行副总裁直接持有 19,899 股公司股票，价值 13,163,984.46 美元。这代表其持股减少了 11.92%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，执行副总裁 Michael G. Erickson 于 2 月 17 日星期二出售了 5,371 股该公司的股票。股票以平均价格 627.38 美元出售，总价值为 3,369,657.98 美元。出售后，该执行副总裁持有 12,693 股该公司的股票，价值约为 7,963,334.34 美元。这代表其持股减少了 29.73%。该交易的 SEC 备案提供了更多信息。过去 90 天内，内部人士共出售了 34,612 股公司股票，价值 22,525,070 美元。当前 0.79% 的股票由内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>IDXX has been the subject of a number of research reports. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a &#34;neutral&#34; rating and a $650.00 price objective for the company. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, February 3rd. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, March 31st. Barclays decreased their price target on IDEXX Laboratories from $850.00 to $800.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, February 5th. Finally, UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $751.00.</p>
<div class="lb-trans"><p>IDXX 最近成为多份研究报告的主题。花旗集团（Citigroup）在 4 月 15 日星期三发布的报告中对 IDEXX Laboratories 开始覆盖。他们为该公司设定了 “中性” 评级和 650.00 美元的目标价。BTIG Research 在 2 月 3 日星期二的报告中将 IDEXX Laboratories 的目标价从 830.00 美元下调至 800.00 美元，并为该公司设定了 “买入” 评级。Stifel Nicolaus 在 3 月 31 日星期二的研究报告中将 IDEXX Laboratories 的目标价从 775.00 美元下调至 675.00 美元，并为该公司设定了 “买入” 评级。巴克莱（Barclays）在 2 月 5 日星期四的研究报告中将 IDEXX Laboratories 的目标价从 850.00 美元下调至 800.00 美元，并为该公司设定了 “增持” 评级。最后，瑞银集团（UBS Group）在 4 月 28 日星期二的研究报告中将 IDEXX Laboratories 的目标价从 730.00 美元下调至 640.00 美元，并为该公司设定了 “中性” 评级。七位分析师对该股票给予了 “买入” 评级，四位分析师给予了 “持有” 评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价为 751.00 美元。</p>
</div><p><strong>Get Our Latest Research Report on IDXX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 IDXX 的最新研究报告</strong></p>
</div><h2>About IDEXX Laboratories</h2>
<div class="lb-trans"><h2>关于 IDEXX Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.</p>
<div class="lb-trans"><p>IDEXX Laboratories, Inc NASDAQ: IDXX 是一家全球开发、制造和提供诊断产品及服务的公司，主要面向动物健康、水质检测和食品安全市场。公司总部位于缅因州的韦斯特布鲁克，提供临床诊断仪器、耗材、参考实验室检测和实践管理工具，支持全球的兽医、畜牧和乳制品生产者，以及公用事业和食品生产者。</p>
</div><p>IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.</p>
<div class="lb-trans"><p>IDEXX 的产品组合包括用于兽医诊所快速诊断的即时检测和免疫测定、临床化学和血液学分析仪、自动化尿液分析系统以及数字诊断解决方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than IDEXX Laboratories</li>
<li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li>
<li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li>
<li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li>
<li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 IDEXX Laboratories 更好的股票</li>
<li>Robinhood、SoFi 和 Webull 讲述了截然不同的故事</li>
<li>随着博通市值突破 2 万亿美元，私人信贷巨头想要入场</li>
<li>通过这些 ETF 关注火热的分拆和合并领域</li>
<li>随着 AI 内存需求激增，三星加入 1 万亿美元俱乐部</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IDXX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IDEXX Laboratories 吗？</h2>
</div><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 IDEXX Laboratories 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 IDEXX Laboratories 并不在名单上。</p>
</div><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IDEXX Laboratories 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX

Market Beat

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

基因免疫&健康关怀 ETF - iShares

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

纽约梅隆银行

景顺投资管理

信安金融

花旗

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Elyxium Wealth LLC 向 IDEXX 实验室公司投资了 36.7 亿美元，股票代码为$IDXX